2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Mike Cusnir, MD, discusses the utilization of ramucirumab in gastric cancer.
Mike Cusnir, MD, co-director of Gastrointestinal Malignancies at Mount Sinai Medical Center, discusses the utilization of ramucirumab (Cyramza) in gastric cancer.
Ramucirumab, according to Cusnir, is one of the more interesting agents in gastric cancer due to an antiangiogenic agent being used in the first- and second-line settings. Data looking at combinations with ramucirumab are emerging and appear promising, according to Cusnir.
The ramucirumab data can be considered in different patient populations, though the agent appears to have the most activity in patients with borderline poor-performance status, concludes Cusnir.